Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,590 matching trials from the live ClinicalTrials.gov search.
Conditions
NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Neurofibromatosis Type 1 (NF1)
Interventions
PAS-004 Tablets, PAS-004 Capsule
Drug
Lead sponsor
Pasithea Therapeutics Corp.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid Cancers, Breast Cancer, Gastric (Stomach) Cancer, Colorectal (Colon or Rectal) Cancer, Sarcoma, Ovarian Adenocarcinoma, Uterine Adenocarcinoma, Endometrial Adenocarcinoma, Esophageal Adenocarcinoma, Head and Neck Cancer, Therapy-Related Acute Myeloid Leukemia, Therapy-Related MDS, Clonal Hematopoiesis of Indeterminate Potential (CHIP), Clonal Cytopenia of Undetermined Significance
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome
Interventions
Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus, Total-Body Irradiation
Drug · Biological · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Withdrawn No phase listed Observational

Axitinib Therapy Management Study

NCT04555603
Conditions
Renal Cell Carcinoma
Interventions
Inlyta, Bavencio, Keytruda
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Photon Therapy, Proton Therapy, Paclitaxel, Carboplatin
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Completed No phase listed Observational

The Platinum Study Comparison Group

NCT02890030
Conditions
Testicular Neoplasms
Interventions
Questionnaire
Behavioral
Lead sponsor
Lawrence Einhorn
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Sarcoma
Interventions
valproic acid
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Conditions
Thyroid Cancer, Thyroid Nodule, Thyroid Neoplasms, Thyroid Goitre, Thyroid Diseases, Parathyroid Diseases, Parathyroid Adenoma, Parathyroid Hyperplasia
Interventions
Acetaminophen 500Mg Cap, Tylenol #3 Oral Tablet, Tramadol
Drug
Lead sponsor
Minerva A Romero Arenas
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Edinburg, Texas
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Methotrexate, Leucovorin calcium, Zidovudine, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Cancer, Patients With Clinical and Environmental Risk Factors for Cancer, Patients With a Suspected or Confirmed Diagnosis of Cancer
Interventions
Patients with CA or suspected risk of CA or a family Hx
Other
Lead sponsor
Greater Baltimore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Simvastatin, Doxorubicin/cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Colon Cancer
Interventions
Metformin
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Recurrent Malignancy, Cytokine Release Syndrome, Allogenic Related Donors, Cell Therapy/Immunotherapy Patients
Interventions
Blood Sample, Stool Sample, Urine Sample, Bronchoalveolar Lavage (BAL) fluid, Gastrointestinal biopsy x 2-4, Skin biopsy, Skin, mouth, and/or ocular swab, Apheresis Product, Final cellular product
Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Breast Cancer, Cardiac Dysfunction
Interventions
Vericiguat, Optimal medical therapy
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Aplastic Anemia
Interventions
Cytoxan, Campath, Total Body Irradiation (TBI), FK-506, Methotrexate, Stem cell infusion
Drug · Radiation · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Minute to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
2
States / cities
Houston, Texas
Conditions
Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, filgrastim, melphalan, methylprednisolone, mycophenolate mofetil, radiation therapy, umbilical cord blood transplantation
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Results available

Lighting Intervention for Cancer-related Fatigue

NCT04827446
Conditions
Breast Cancer, Prostate Cancer, Hematologic Malignancy, Survivorship, Fatigue
Interventions
Wearable Sensor, Blue-blocking glasses, Clear glasses, Full SYNC app, "Dummy" SYNC app
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Liver Cancer Adult, Liver Regeneration
Interventions
carbon monoxide measurement via smokerlyzer
Other
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
1
States / cities
Englewood, New Jersey
Conditions
Breast Cancer, Cardiotoxicity
Interventions
Proton vs Photon Radiation
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Warrenville, Illinois • Baltimore, Maryland + 3 more
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
San Antonio, Texas
Conditions
Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Drug Toxicity, Radiation Toxicity, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions
External Beam Radiation Therapy, Cisplatin, Internal Radiation Therapy, Epoetin Alfa
Radiation · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Phoenix, Arizona
Completed No phase listed Observational Accepts healthy volunteers

Work-Related Effects of Heat, Activity, and Fat in Middle Aged Men

NCT02532725
Conditions
Obesity, Gender, Problem of Aging
Interventions
Cardiopulmonary Exercise Stress Test, Climatic-Controlled Cardiopulmonary Exercise Stress Test, Body Composition Evaluation, Pre-Exercise Risk Assessment
Procedure
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
35 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1972
U.S. locations
1
States / cities
Buckhannon, West Virginia
Completed No phase listed Observational Results available

COVID19 OutcomeS in Myeloma and the Impact of VaCcines

NCT05831787
Conditions
Multiple Myeloma
Interventions
Patient Reported Outcomes
Other
Lead sponsor
ASH Research Collaborative
Other
Eligibility
Not listed
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina